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Objectives:	 It has been suggested that radiation can enhance the apoptosis-inducing 
efficacy of the TNF Related Apoptosis Inducing Ligand (TRAIL). Whether or not this is a 
general effect seen in all TRAIL receptor-positive cell lines and whether or not this also 
enhances the ultimate loss of clonogenicity of tumor cells remains to be elucidated. In 
this study we evaluated the effect of combined γ-radiation-TRAIL therapy in a gliob-
lastoma cell line, measuring both early apoptotic cell death and clonogenic ability as 
endpoints. 
Methods:	Glioblastoma A172 cells were treated by TRAIL, radiation or a combination of 
both treatments and cell death was analyzed by short term assays (Crystal Violet; FACS 
analysis) and a long term assay (clonogenic). Cell surface expression of the TRAIL recep-
tor before and after radiation was evaluated by flow cytometry. 
Results:	Glioblastoma A172 cells expressed both the TRAIL R1 and –R2 receptor on the 
cell surface, but radiation did not increase the cell surface expression of these 2 recep-
tors. Yet, the combination of radiation and TRAIL lead to a small synergy in apoptosis 
induction. However, this did not translate to synergy in ultimate loss of clonogenicity 
where radiation and TRAIL merely showed additive effects.
Conclusion:	Up-regulation of TRAIL receptors by radiation does not seem a generic fea-
ture that is seen in all cell lines. Synergistic induction of apoptosis can occur, either via 
upregulation of TRAIL receptors (literature studies) or via dual triggering of synergizing 
signaling pathways that induce apoptosis (as suggestive from this study). This, however, 
does not (always) results in synergy at the level of clonogenic ability. Therefore when 
combining TRAIL treatment as an adjuvant to radiotherapy in the treatment of patients 






Glioblastoma multiforme tumors (GBM) tumors have been shown to be intrinsically 
resistant to radiation and although radiation has effect on overall survival, cures are not 
obtained. The development of new treatment modalities for patients with a GBM with the 
primary goal to enhance survival is an ongoing process. Such a new treatment modality 
could be the death inducing ligand TRAIL in combination with radiation. The subject of 
this paper is the death inducing effect of TRAIL in combination with radiation in a gliob-
lastoma cell line.  
Recombinant human TNF Related Apoptosis Inducing Ligand (rhTRAIL), a soluble death 
inducing ligand, induces cell death via binding to the transmembranous TRAIL-R1 and/or 
TRAIL-R2 receptors which triggers apoptosis. In a previous study we detected the pres-
ence of TRAIL-R1 and TRAIL-R2 receptors on primary GBM tumor tissue and showed the 
association of these receptors with tumor cell survival [1]. Various in vitro and animal in vivo 
experiments have shown the death inducing potential of TRAIL, without obvious toxicity for 
normal cells [2,3]. These results may implicate that rhTRAIL can be used as a therapeutic 
modality in the treatment of patients with various tumors, including those patients with a 
GBM.  Unfortunately some GBM cell lines show also resistance to TRAIL [4,5]. 
An option may be to combine radiation and rhTRAIL to overcome resistance to either 
therapy.  In several in vitro and ex vivo studies on non-GBM cells this was shown to 
be an effective combination therapy [6-11]. In fact, it has been suggested for leukemic 
and breast cancer cells that radiation upregulates TRAIL-receptors and enhances its 
cell surface expression, hereby enhancing the cellular sensitivity to TRAIL-mediated cell 
killing [10,11,8]. In contrast to this idea, Ciusani et al. [12] found no detectable effect of 
radiation (2Gy) on TRAIL receptor expression in two brain tumor cell lines (U373 and the 
SW1783). They also reported (data not shown) that apoptosis measurement (Annexin-V) 
after combinational treatment showed a modest (SW1783) to no (U373) increase in the 
number of apoptotic cells. 
Most papers, addressing the combinational effect of radiation and TRAIL agonists, 
evaluate apoptosis as a short term end-point. Therefore, these studies do not take into 
account other modes of cell death that influence ultimate loss of clonogenicity of tumor 
cells. In other words, the same cells that would normally die late after radiation due to 
mitotic catastrophe may now die earlier from rhTRAIL induced  (early) apoptosis due to 
radiation-induced upregulation of the TRAIL receptors, meaning that tumor cell death 
would be accelerated but ultimately not increased.  This could lead to false conclu-
sions regarding the potential enhancing effect of radiation on TRAIL and vice versa. In 
this study we therefore re-evaluated the effect of γ-radiation in combination with TRAIL 
therapy in a glioma cell line, evaluating both early apoptotic cell death and clonogenic 





The glioblastoma cell line A172 was purchased from ATCC (Manassas, USA). A172 
cells were cultured in DMEM, supplemented with 10% fetal calf serum (FCS) and 4 mM 
L-glutamine (Cambrex Bio Science) at 37°C in humidified 5% CO2 atmosphere. 
TRAIL,	antibodies	and	DiOC6
Recombinant human soluble TRAIL (rhTRAIL) was kindly provided by S. de Jong 
(University Medical Center Groningen, University of Groningen, Department of Internal 
Medicine, section Medical Oncology). Monoclonal (human) antibodies against TRAIL 
receptor TRAIL-R1 and TRAIL-R2 were purchased from Alexis Biochemicals (Benelux). 
Phycoerythrin-labeled goat anti-mouse IgG (GAM-PE) was used as a secondary antibody 
(DakoCytomation, Denmark). The cell-permeant green-fluorescent lipophylic dye DiOC6 
was purchased from Molecular Probes, Eugene, OR. 
Radiation
Cells were washed twice with phosphate buffered saline (PBS) and trypsinized, followed by 
neutralisation of trypsin with DMEM medium. After centrifugation (1500 rpm for 8 minutes) 
cells were resuspended in fresh medium at a concentration of 5 * 105 cells/ml (clonogenic 
assay) or 1 * 106 cells/ml (crystal violet assay, flow cytometry). In all experiments (unless 
mentioned otherwise), radiation was performed in suspension, using a 137-Cs gamma ray 
unit (IBL 637, CIS Biointernational, GIF sur Yvette, France) at a dose rate of 0,7895 Gy/min. 
Flow	cytometry
Flow cytometric analysis was performed at various intervals after radiation (8, 24 and 
48 hrs). Cells were irradiated while plated (and attached) in T75 flasks. After radiation 
with 2 or 5 Gy, flasks were put back in a culture stove (37°C, 5% CO2). At the day of 
analysis, cells were washed twice with PBS and trypsinized. Cells were resuspended in 
fresh medium at a concentration of 5 * 105 cells/ml. After centrifugation (1600 rpm for 5 
minutes) cells were resuspended in medium containing the various antibodies (aTRAIL-
R1, aTRAIL-R2). Cells were incubated for 40 minutes on ice. After washing the cells with 
fresh medium, cells were incubated with the secondary antibody, GAM-PE, for 40 min-
utes (on ice). Cells were then washed twice with fresh medium and FACS analysis was 
performed using the ELITE flow cytometer. 
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Apoptosis was also measured using flow cytometry. Cells were harvested and radiated 
with 2 or 5 Gy. After radiation, cells were plated in 12-well plates (0,5 * 106 cells/well). 
Eight hours after radiation, rhTRAIL or medium was added to the different wells. The next 
day, all cells (adherent and non-adherent) were harvested. After centrifugation, cells were 
resuspended and DiOC6 was added. After incubation for 30 minutes at 37°C, cells were 
washed and analyzed by the Calibur flow cytometer. 
Crystal	violet	viability	assay
Tumor cell viability was assessed by a crystal violet assay. Cells were washed twice with 
PBS and trypsinized, followed by neutralisation of the trypsin with DMEM medium. After 
centrifugation (1500 rpm for 8 minutes) cells were resuspended in fresh medium and 
radiated. After radiation, cells were seeded in flat-bottom 96-well microculture plates 
at a concentration of 3*104 cells/well in 200 μl medium. Eight hours after radiation, 100 
μl medium was removed and replaced by 100 μl fresh medium containing the various 
concentrations of rhTRAIL. Cells were reincubated overnight cells followed by a washing 
with PBS, staining with crystal violet solution and solubilized in 1% SDS. Absorbance 
was read at 575 nm by an ELISA-plate reader.
Clonogenic	assay
Cells were washed twice with PBS and trypsinized. Cells were radiated and plated in 60 
mm petri-dishes. Appropriate dilutions were made to yield 50 – 100 colonies per petri-
dish. After plating the sample cells, 105 feeder cells (cells lethally radiated with 100 Gy) 
were added to each plate. Eight hours after radiation, rhTRAIL was added. Cells were 
stored in an incubator at 37°C and 5% CO2, for 12 – 14 days. After this period the medi-
um was removed and cells were washed once with PBS. After fixating with 70% ethanol, 
cells were stained with 1% crystal violet solution and washed twice in tap water. 
Colonies containing more than 50 cells were counted. Survival was calculated with the 
formula: (Number of colonies counted/number of cells plated) x (1/plating efficiency)
The plating efficiency (PE) is the colony count resulting from 100 untreated cells. In this 
study, the PE of A172 cells was 65%. 
Data	analysis	and	statistics
Interactions between TRAIL and radiation were analyzed by the fractional inhibition 
method13. When expressed as the fractional inhibition cell viability, additive inhibition 
produced by both inhibitors (Ia,b) occurs when Ia,b =Ia + Ib; synergism when Ia,b >Ia + 
Ib and antagonism when Ia,b< Ia + Ib. Differences between two groups were tested for 
significance using a two-tailed non-parametric Mann-Whitey test. Differences between 
multiple groups (>2) were tested using one-way analysis of variance (ANOVA).
Results
Early	cell	death	induced	by	rhTRAIL	and	radiation
First,  we tested if combined treatment of radiation and recombinant human (rh) TRAIL 
would lead to enhancement of cell death in glioblastoma A172 cells using the crystal violet 
assay (Figure 1A). Rapid cell death after radiation alone was only 4%. Recombinant human 
(rh)TRAIL resulted in respectively 45% (10 ng/ml) and 65% (100 ng/ml) apoptosis. The 
combined treatment of radiation and rhTRAIL induced a significantly higher fraction of cell 
death than rhTRAIL alone (55% respectively 77% for 10 ng/ml and 100 ng/ml (p=0.01)). In 
Figure 1B it can be seen that the extent of rapid cell death after the combined treatment 
was significantly synergistic, albeit that the magnitude of the synergistic effect was small 
(rhTRAIL 10 ng/ml: p = 0,04; rhTRAIL 100 ng/ml: p = 0,02). 
To test whether the rapid cell death was indeed due to increased apoptosis induction, we 
used flow cytometry. Figure 2 (pg 192) shows the FACS results of A172 cells after treat-
ment with rhTRAIL, radiation or a combination of rhTRAIL and radiation. The fraction of 
apoptotic cells (cell under the pre G1 peak) increased from 5% (no treatment) to 40% and 
77% after 10 or 100 ng/ml rhTRAIL respectively (Figure 2A, pg 192). After irradiation (2Gy) 
alone 11% of cells are apoptotic by these criteria (Figure 2B, pg 192). The combined treat-
ment of radiation and rhTRAIL (10 ng/ml and 100 ng/ml) resulted respectively in 54.93% 
and 90.91% apoptosis. So, these data are consistent with the crystal violet data (Figure 1) 
and with the idea that this assay predominantly registers apoptotic cell death.
Clonogenic	assay	shows	additive	killing	after	combination	treatment	
To test whether the combined treatments not only accelerate cell death but also increase 
the ultimate level of cell death, we evaluated the ability of cells to form colonies after the 
single and combined treatments (Figure 3). Remarkably, whereas the early cell death 
assays only revealed 4% (crystal violet) respectively 11 % (FACS) cell death after 2Gy 
alone, only 25% of the cells were able to form colonies after this dose of radiation. This 
indicates that early apoptotic cell death only plays a minor role in radiation-induced cell 
death of A172 cells. 
Cell survival was reduced in the non-irradiated group to 84,3%, 23,0% and 0,009% after 
1, 5 and 10 ng/ml rhTRAIL respectively (Figure 3). Compared to the 40-45% apoptotic cell 
death after 10 ng/ml rhTRAIL in the short term assays (Figure 1 and 2 (pg 192)) this means 
that even TRAIL induces additional (delayed) cell death through non-classical pathways 
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besides via rapid apoptosis alone. Treatment with 100 ng/ml rhTRAIL could not be ana-
lyzed due to the massive toxicity in the clonogenic assay (no colonies were detected).
As shown in Figure 3, the combined treatment with 2 Gy radiation and variable rhTRAIL 
concentrations (1, 5, 10 ng/ml) had merely additive effects on the clonogenicity of glioma 
cells. After treatment with radiation and 10 ng/ml TRAIL, there were no colonies found in 
plates where 40.000 cells were plated. Therefore, cell survival after this combined treat-
ment was indicated as less than 0,0025% (shown by the arrow in Figure 3). So, although 
the combined treatments led to slightly more than additive rapid apoptosis, no enhance-
ment of ultimate cell death was seen after the combination treatment.
TRAIL	receptor	expression	is	not	increased	after	radiation	
To test the idea that radiation may up-regulate TRAIL receptors at the cell surface and 
as such increase rapid apoptosis, we evaluated the cell surface expression of the TRAIL 
receptors TRAIL-R1 and TRAIL–R2 in A172 cells, by flow cytometry. Only 2,1% of the A172 
cells expressed TRAIL-R1, whereas TRAIL-R2 was present on 99,2% of the cells (data 
not shown). After radiation (2 or 5 Gy), no significant radiation dependent changes were 
detectable in the expression of these two TRAIL receptors (Figure 4 and 5).  The overall 
expression of TRAIL-R1 receptors did increase with time within all experimental groups, 
however, no statistical difference could be found in this increase between the control 
group and the radiation groups (Figure 4A). Also the number of TRAIL-R1 receptor positive 
cells remains extremely low over time and there was no significant increase after radiation 
(Figure 4B).  Although upregulation of TRAIL-R2 receptor expression was seen after radia-
tion, this effect was not significant and independent of time after radiation (Figure 5A). Also, 
the percentage of TRAIL-R2 positive cells was high and remained high with time without 
being affected by radiation (Figure 5B). 
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Rapid cell death induced as determined by the Crystal Violet assay after radiation, rhTRAIL (10 and 
100 ng/ml) or a sequential treatment of radiation and rhTRAIL. 
Panel A: Fraction of cell death after the respective treatments (* = rhTRAIL).
Panel B: comparison between the “observed” cell death and the calculated “additive” effect of both 
treatments (TRAIL 10= TRAIL 10 ng/ml). Data points represent the means and 95% confidence inter-




Clonogenic survival of A172 cells after treatment with graded concentrations of rhTRAIL either given 
alone (control, squares) or in combination with 2Gy irradiation (circles). The parallel lines indicate an 
additive effect of the combined treatment with radiation and rhTRAIL. The plating efficiency of the 
untreated A172 cells was 65 and set as 100%. ↓: Less than 0,0025% survival. This figure is a repre-




Effect of radiation on TRAIL-R1 cell surface expression (panel A) and the percentage of TRAIL-R1 
positive cells as measured by FACS analyses. 
Panel A shows the mean fluorescence intensity as a function of time in culture of untreated cells (tri-
angles) or after irradiation of the cells with 2 Gy (diamonds) or 5 Gy (squares). The mean fluorescent 
intensity immediately after (sham) treatment of control cells was set as 100%. Bars represent SD of 
two independent experiments.
Panel B shows the fraction of cells with cell surface expression of the TRAIL-R1 receptor as a func-
tion of time in culture of untreated cells (triangles) or after irradiation of the cells with 2 Gy (diamonds) 




Effect of radiation on TRAIL-R2 cell surface expression (panel A) and the percentage of TRAIL-R2 
positive cells as measured by FACS analyses. 
Panel A shows the mean fluorescence intensity as a function of time in culture of untreated cells (tri-
angles) or after irradiation of the cells with 2 Gy (diamonds) or 5 Gy (squares). The mean fluorescent 
intensity immediately after (sham) treatment of control cells was set as 100%. Bars express SD of 
two independent experiments. Panel B shows the fraction of cells with cell surface expression of the 
TRAIL-R2 receptor as a function of time in culture of untreated cells (triangles) or after irradiation of 






It had been suggested by several investigators that radiation may lead to an enhancement 
of TRAIL-toxicity and as such this combined modality may have therapeutic potential. 
[6-12,14] In most cases, the effect of radiation and TRAIL on cell survival had been only 
investigated using short term viability assays (crystal violet, MTT). [6-11,14] However, 
these assays do not take into account (later) cell death e.g. due to mitotic catastrophy 
of cells that did not undergo apoptosis initially. As we show here for radiation, such can 
lead to a dramatic underestimation of ultimate loss of reproductive capacity of cells (the 
ultimate goal in cancer therapy) as it is detected by clonogenic assay. Similar data were 
reported in a recent study by Nagane et al. [14]. In their study, a synergistic effect on 
apoptosis (TUNEL assay) by the combination therapy was found in 2 cell lines (T98G 
and U251). However, in only one cell line (T98G) this translated into some synergy when 
evaluated by the clonogenic assay. In the other cell line (U251) only additivity was found 
for this endpoint, like what we show here for the A172 cells. Therefore short term assays 
may be mis-interpreted in terms of synergy if certain treatments lead to accelerated 
(apoptotic) cell death without having an effect of the extent of ultimate cell death.  
In our current study, we tried to test whether radiation would also synergistically interact 
with TRAIL in inducing cell death in a glioblastoma cell line A172 in order to bypass the 
typical radio-resistance of GBM tumor cells. Although, we found borderline significant 
synergy for early cell death induction (apoptosis, MTT), as was found by many others 
[6-12,14]  no evidence was found to support the idea that the combination treatment 
enhanced the extent of ultimate killing (clonogenic assay) of radio-resistant A172 cells. 
Rather, the treatments were additive.
A possible explanation of synergistic apoptosis induction after combination treatment, 
which is frequently stated in the literature, could be radiation-induced upregulation of 
TRAIL receptors, thereby enhancing receptor modulated rhTRAIL killing [7,14,15]. In this 
study, no radiation-induced upregulation of membrane bound TRAIL-R1/R2 receptors 
in A172 cells was detected. Nor was a detectable increase found in the fraction of cells 
that expressed these receptors at their surface. This may explain why we only found 
borderline synergy for early death induction. The fact that still some synergy is found may 
indicate that radiation triggers some signaling pathways that facilitate TRAIL-induced 
apoptosis or vice versa. In any case, the effect we found in glioma cells was minor and 
consistent with Ciusani et al. who also found no up-regulation of TRAIL receptors (FACS 
analysis) after ionizing radiation (2 Gy) on glioma cell lines [12]. Yet, Nagane et al. did 
find up-regulation of  TRAIL-R2 protein levels after radiation in some of the glioma cell 
lines investigated [14]. However, they did not evaluate whether this also lead to increased 
membrane receptor expression. So unlike other cell lines such as acute T lymphoblastic 
leukemia (MOLT-4) cells [11] and colorectal carcinoma (Colo205; HCT-15), lung (NCI-
H460)[16] and breast carcinoma cells (MCF7)[10],  several glioma cells may be  radiation 
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resistant in terms of up-regulating these receptors and this may in fact contribute to a 
reduced is situ tumor radio-resistance on top of their intrinsic cellular radio-resistance. 
Besides the conclusion that glioma cells may not show (much) synergy between radiation 
and TRAIL, our data also argue for re-evaluation of the observed synergy between these 
modalities seen in rapid death endpoint assays in other cell lines [6-12]. In none of these 
studies the efficacy of TRAIL and radiation was determined used a clonogenic assay. In 
fact, our finding that the extent of TRAIL-induced clonogenic death exceeded the extent 
of rapid apoptotic cell death underscores the need for such re-evaluation.
Finally, our findings demonstrate that glioma cells do express TRAIL receptors at their 
cell surface and are sensitive to TRAIL-induced cell death. This implies that glioma radio-
resistance may not be associated with a cross-resistance to TRAIL. Hence, our study 
does not exclude rhTRAIL treatment as an adjuvant therapy in the treatment of patients 
with a malignant brain tumor. However, although only one glioma cell line was studied 
here, our data combined with Nagane et al. [14] suggest that a synergistic interaction 
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